Results
Seventeen studies (which enrolled 1836 patients) met the inclusion criteria. Patients received adequate enteral nutrition in three of the studies. Overall, stress ulcer prophylaxis with a histamine-2 receptor blocker reduced the risk of gastrointestinal bleeding (odds ratio 0.47; 95% confi dence interval, 0.29-0.76; P < 0.002; Heterogeneity [I 2 ] = 44%); however, the treatment eff ect was noted only in the subgroup of patients who did not receive enteral nutrition. In those patients who were fed enterally, stress ulcer prophylaxis did not alter the risk of gastrointestinal bleeding (odds ratio 1.26; 95% confi dence interval, 0.43-3.7). Overall histamine-2 receptor blockers did not increase the risk of hospital-acquired pneumonia (odds ratio 1.53; 95% confi dence interval, 0.89 -2.61; P = 0.12; I 2 = 41%); however, this complication was increased in the subgroup of patients who were fed enterally (odds ratio 2.81; 95% confi dence interval, 1.20-6.56; P = 0.02; I 2 = 0%). Overall, stress ulcer prophylaxis had no eff ect on hospital mortality (odds ratio 1.03; 95% confi dence interval, 0.78-1.37; P = 0.82). Th e hospital mortality was, however, higher in those studies (n = 2) in which patients were fed enterally and received a histamine-2 receptor blocker (odds ratio 1.89; 95% confi dence interval, 1.04-3.44; P = 0.04, I 2 = 0%). Sensitivity analysis and metaregression demonstrated no relationship between the treatment eff ect (risk of gastrointestinal bleeding) and the classifi cation used to defi ne gastrointestinal bleeding, the Jadad quality score or the year the study was reported.
Conclusions
Th e results of this meta-analysis suggest that, in those patients receiving enteral nutrition, stress ulcer prophylaxis may not be required and, indeed, such therapy may increase the risk of pneumonia and death. However, because no clinical study has prospectively tested the infl uence of enteral nutrition on the risk of stress ulcer prophylaxis, those fi ndings should be considered exploratory and interpreted with some caution.
Commentary
In 1969, Skillman et al. [1] reported a clinical syndrome of lethal "stress ulceration" in seven of 150 (5%) consecutive intensive care unit (ICU) patients. Th ese patients had in common respiratory failure, hypotension, and sepsis. Subsequent studies confi rmed this fi nding and two meta-analyses published by Cook et al. [2] demonstrated that both histamine-2 receptor blockers (H2RBs) and sucralfate decreased the risk of bleeding from stress ulceration when compared to a placebo. Stress ulcer prophylaxis (SUP) becomes regarded as the standard of care in patients admitted to the intensive Care Unit (ICU), and this intervention is currently endorsed by Surviving sepsis campaign and American Society of Health System Pharmacists (ASHP) guidelines. Th e universal use of SUP has been reinforced with the adoption of "ventilator bundles. " Currently Joint Commission and the Institute for Healthcare Improvement recommend universal SUP as a core "quality" measure for mechanically ventilated patients.
Although the Agency for Healthcare Research and Quality recommends using SUP only in patients on mechanical ventilation and high bleeding risk from coagulopathies, SUP is used in all critically ill patients and even outside the ICU setting. For example, estimates indicate that approximately 90% of critically ill patients admitted to the ICU receive some form of SUP [3] , and up to 52% of non-ICU patients receive SUP [4, 5] . SUP is not without risks. Acid suppressive therapy is associated with increased colonization of the upper gastrointestinal tract with potentially pathogenic organisms and may increase the risk of hospital-acquired pneumonia [5] . Furthermore, gastric acid is an important defense against the acquisition of Clostridium diffi cile spores, and the use of acid suppressive therapy has been linked to an increased risk of Clostridium diffi cile infection [6] [7] [8] . Th us, understanding risks and benefi ts of SUP is important. For example, patients receiving enteral alimentation have a lower incidence of stress ulceration than unfed patients [9] . Whether routine SUP in patients who receive enteral feeding is benefi cial or harmful is not known.
Marik et al. [10] conducted a meta-analysis of 17 randomized clinical trials and postulated that SUP may have no added benefi ts in ICU patients who receive enteral nutrition. Th ey examined the eff ect of diff erent SUP regimes on the risk of gastrointestinal bleeding, hospital-acquired pneumonia, and mortality, stratifying the studies based on enteral nutrition.
Th e meta-analysis included a total of 1836 enrolled between the years 1980 and 2004. Overall, SUP with a H2RB reduced the risk of GI bleeding (P < 0.002) but had no eff ect on mortality. Th e benefi cial eff ect of SUP was noted only in the subgroup of patients who did not receive enteral nutrition. SUP did not alter the risk of GI bleeding in patients who received enteral nutrition, and these individuals had higher risk of hospital-acquired pneumonia (P = 0.02, n = 9 studies) and mortality (P = 0.04, n = 2 studies).
Th e results of this meta-analysis suggest that SUP may not be benefi cial in patients who are fed enterally. Th e strength of this review article includes the rigorous attempt to identify all relevant RCTs studies, consider and evaluate for possible confounding factors, such as year of publications, defi nition of gastrointestinal bleeding, quality of randomized controlled trials, and publication bias. Limitations of this article includes lack of homogeneity in patient population, diff erence in diagnostic criteria used for major end-points, and only three studies had patients with enteral nutrition.
Recommendation
SUP is benefi cial in high risk patients, including those that are on mechanical ventilation and have coagulopathy. SUP may cause unfavorable outcomes, such as hospitalacquired pneumonia and Clostridium diffi cile infection, and clinicians must weigh risks and benefi ts in low-risk patients, such as those who are not requiring mechanical ventilation or are receiving enteral nutrition.
